Please assess the completion status of the following clinical trial:

Trial Title: Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Electrocardiographically documented, symptomatic paroxysmal AF.~* Patients with indication for left atrial ablation of AF according to ESC guidelines for the management of atrial fibrillation.~* Anticoagulation according to clinical routine using coumarin derivates with target INR between 2.0 and 3.0 at least 3 weeks prior to the scheduled ablation procedure or novel oral anticoagulants (NOACs).~* Geographically stable for the duration of the study.~* Willingness and ability to perform written informed consent~Exclusion Criteria:~* Long standing persistent or persistent AF~* CHA2DS2-VASc score ≥ 5~* Prior ischemic stroke or Transient Ischemic Attack~* Previous Pulmonary Vein ablation~* Contraindication for anticoagulation therapy~* Contraindication for Diffusion-Weighted MRI~* Claustrophobia~* Contraindication for transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE, if TEE not possible)~* Implanted cardiovascular device, including but not limited to an atrial or ventricular pacemaker or defibrillator leads, artificial valves, stents, septal or LAA occluders~* Acute coronary syndrome \< 3 months prior to scheduled ablation~* Moderate to severe valvular heart disease~* LA size \> 55 mm (confirming echo at maximum 3 months old)~* Patients with non-controlled heart failure or patients with current and recent (\< 1 month prior to ablation) heart failure~* Ejection fraction \< 35% (confirming echo at maximum 3 months old)~* Conditions that prevent patient's participation in neurocognitive assessment (at physician's discretion)~* Female patients who are pregnant or breast feeding or plan a pregnancy during the course of the study~* Any limitation to contractual capability~* Simultaneous participation in another study~* Age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing

Based on this trial design, predict the completion outcome and termination type (if applicable).